AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

Sponsor:  Ohio ENT & Allergy Physicians Do any of these symptoms sound familiar: Stuff or Runny Nose? Headaches? Sinus ...

If nasal congestion persists, pus can accumulate in the sinuses and inflammation can spread If inflammation continues, polyps can also develop in the sinuses I thought, if this continues ...

Some essential oils may clear up nasal passages and relieve sinus pressure and other congestion symptoms. Sinus congestion is uncomfortable to say the least. It may make it difficult for you to ...

Spring is in full swing and perhaps you’ve found yourself battling nasal congestion. Three common causes are colds, hay fever and sinusitis. Nasal congestion happens when something irritates the ...

Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...